Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/30/2010CA2335477C Sulfonamide inhibitors of aspartyl protease
11/30/2010CA2326653C Compositions and methods of adjusting steroid hormone metabolism through facilitated absorption of hydrophobic dietary compounds
11/30/2010CA2315693C Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
11/30/2010CA2299295C Substituted tetrahydropyrane derivatives and method for producing same
11/30/2010CA2295876C Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
11/30/2010CA2259595C Dna immunization against chlamydia infection
11/25/2010WO2010135748A1 Bimacrocyclic hcv ns3 protease inhibitors
11/25/2010WO2010135736A2 Application and uses of prg4 and therapeutic modulation thereof
11/25/2010WO2010135716A1 Trans-acting rna switches
11/25/2010WO2010135714A2 Methods for modulating adipocyte expression using microrna compositions
11/25/2010WO2010135695A2 TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
11/25/2010WO2010135690A1 Antiviral treatment of lymphoma and cancer
11/25/2010WO2010135662A2 Marker differentially expressed in cancer stem cells and methods of using same
11/25/2010WO2010135650A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
11/25/2010WO2010135643A1 Formation of accumbens glur2-lacking ampa receptors mediates incubation of cocaine craving
11/25/2010WO2010135621A1 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
11/25/2010WO2010135581A1 Pyrazolopyrimidines and related heterocycles as kinase inhibitors
11/25/2010WO2010135579A1 Fluorinated diaryl urea derivatives
11/25/2010WO2010135571A1 Novel protein kinase modulators
11/25/2010WO2010135570A1 Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure
11/25/2010WO2010135569A1 N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production
11/25/2010WO2010135568A1 Benzoxazepines as inhibitors of mtor and their use to treat cancer
11/25/2010WO2010135560A1 Modulators of 5-ht receptors and methods of use thereof
11/25/2010WO2010135536A2 Methods of modulating uric acid levels
11/25/2010WO2010135534A2 Compositions for the treatment of metastatic cancer and methods of use thereof
11/25/2010WO2010135527A2 Elastin for soft tissue augmentation
11/25/2010WO2010135524A1 Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
11/25/2010WO2010135520A1 Compounds, compositions and methods for treating viral infection
11/25/2010WO2010135506A1 Process for the preparation of 4- [6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
11/25/2010WO2010135493A2 Alzheimer's disease imaging agents
11/25/2010WO2010135470A1 Pifenidone derivatives for treating bronchial asthma
11/25/2010WO2010135452A2 Pyrazinamide for the treatment of leishmaniases
11/25/2010WO2010135449A1 Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing
11/25/2010WO2010135429A2 Compositions for modulating a kinase cascade and methods of use thereof
11/25/2010WO2010135427A2 Trioxane monomers and dimers
11/25/2010WO2010135426A1 Methods of treating liposarcoma
11/25/2010WO2010135424A1 Chemical compounds
11/25/2010WO2010135404A1 Ep2 receptor agonist from non-prostanoid structures designed as pge2 antagonists
11/25/2010WO2010135396A2 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
11/25/2010WO2010135329A2 Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
11/25/2010WO2010135322A1 Methods and devices for improved efficiency of rna delivery to cells
11/25/2010WO2010135264A1 Analgesic compositions
11/25/2010WO2010135247A1 Compositions and methods for increasing telomerase activity
11/25/2010WO2010135170A2 Nitrile derivatives and their pharmaceutical use and compositions
11/25/2010WO2010135014A1 Tri-cyclic pyrazolopyridine kinase inhibitors
11/25/2010WO2010134971A1 Optimal compositions and methods for treating oral disease and pain
11/25/2010WO2010134965A1 Solid pharmaceutical compositions and processes for their production
11/25/2010WO2010134939A2 Mammalian genes involved in infection
11/25/2010WO2010134938A1 Modified release niacin pharmaceutical formulations
11/25/2010WO2010134904A1 Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
11/25/2010WO2010134851A1 Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
11/25/2010WO2010134846A1 Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1h-gamma-carbolines, ligands and pharmaceutical composition; method for the production and use of same
11/25/2010WO2010134830A1 Triterpenoid derivatives useful as antiproliferative agents
11/25/2010WO2010134790A2 Anti-inflammatory composition containing macrolactin a and a derivative thereof as active ingredients
11/25/2010WO2010134614A1 SELF-EMULSIFYING COMPOSITION OF ω3 FATTY ACID
11/25/2010WO2010134595A1 Anti-obesity agent comprising compound containing benzotropolone ring
11/25/2010WO2010134588A1 Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
11/25/2010WO2010134574A1 Orally disintegrating tablet
11/25/2010WO2010134556A1 Aqueous injection solution containing 5-methyl-2-(1-piperazinyl)benzenesulfonic acid derivative
11/25/2010WO2010134540A1 Dry-coated orally-disintegrating tablet
11/25/2010WO2010134533A1 2,4-diaminopyrimidine compound having aminocyclohexylalkyl group
11/25/2010WO2010134433A1 Transdermal preparation
11/25/2010WO2010134373A1 Prophylactic and/or therapeutic agent for metabolic syndrome
11/25/2010WO2010134117A1 Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility
11/25/2010WO2010134091A1 A process for preparation of a non-antibiotic growth promoter formula / product and its use in food animals
11/25/2010WO2010134087A1 Water dispersible glyceryl monooleate magnetic nanoparticle formulation
11/25/2010WO2010134085A1 Pharmaceutical co-crystals of quercetin
11/25/2010WO2010134082A1 Chromenone derivatives for treatment of cancer
11/25/2010WO2010134074A1 Compositions for continuous administration of dopa decarboxylase inhibitors
11/25/2010WO2010134067A1 A3 adenosine receptor agonists for the reduction of intraocular pressure
11/25/2010WO2010134048A2 Topical retinoid solutions
11/25/2010WO2010134047A2 Liquid dosage forms of isotretinoin
11/25/2010WO2010134045A1 Amorphous fosamprenavir calcium
11/25/2010WO2010134039A2 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
11/25/2010WO2010134032A1 Use of inhibitors of zdhhc2 activity for modulation of adipogenesis
11/25/2010WO2010134025A2 Oral compositions of celecoxib
11/25/2010WO2010133973A1 1,4 dihydropyridine derivatives and their uses
11/25/2010WO2010133970A1 Targeting micrornas for metabolic disorders
11/25/2010WO2010133961A1 Extended release compositions of cyclobenzaprine
11/25/2010WO2010133907A1 Hexadentate chelators in inflammatory bowel disease
11/25/2010WO2010133906A2 Use of specific chelating polymers in medicaments for the treatment of inflammatory bowel disease
11/25/2010WO2010133885A1 Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
11/25/2010WO2010133882A1 Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamin0)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate
11/25/2010WO2010133836A1 Fused bicyclic pyrazole derivatives as kinase inhibitors
11/25/2010WO2010133815A1 Treatment of heart failure with normal ejection fraction
11/25/2010WO2010133794A1 Anticancer compound and pharmaceutical composition containing the same
11/25/2010WO2010133793A1 Drug containing calcium and vitamin d
11/25/2010WO2010133761A1 Intravaginal delivery system comprising one or more therapeutically active substances capable of preventing and/or treating vaginal infections
11/25/2010WO2010133757A1 Vaginal delivery system
11/25/2010WO2010133748A1 Protease inhibitors
11/25/2010WO2010133742A1 Use of quinazoline derivatives for neurodegenerative diseases
11/25/2010WO2010133700A1 Pharmaceutical composition comprising microbubbles for targeted tumor therapy
11/25/2010WO2010133687A1 Cycloartanone derivatives with anticancer activity
11/25/2010WO2010133672A1 Derivatives of quinoline-3-carboxylic acid and their medical use
11/25/2010WO2010133669A1 Substituted quinolines for use as vegf inhibitors
11/25/2010WO2010133663A1 Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
11/25/2010WO2010133652A1 Multimodal activity of g-quartet oligonucleotides and microbicide compositions
11/25/2010WO2010133647A1 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
11/25/2010WO2010133638A1 Pharmaceutical oral telmisartan solution
11/25/2010WO2010133598A1 Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl)pyridine and their therapeutical uses
1 ... 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 ... 7860